

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BenQ BM Holding Cayman Corp.

明基醫院集團股份有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Code: 2581)

**(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
(2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
AND
(3) CHANGE IN COMPOSITION OF BOARD COMMITTEES**

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of BenQ BM Holding Cayman Corp. (the “**Company**”) hereby announces that Mr. CHEN Ray-Jade (陳瑞杰) (“**Mr. Chen**”) resigned as an independent non-executive Director of the Company, the chairman of the remuneration committee and a member of the nomination committee of the Company, all with effect from August 6, 2026 due to his plans to devote more time in other business and personal commitments.

Mr. Chen has confirmed to the Company that he has no disagreement with the Board and there were no matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. Chen for his valuable contribution to the Company during his tenure of service.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Prof. CHEN Shi-An (陳適安) (“**Prof. Chen**”) has been appointed as an independent non-executive Director of the Company with effect from August 6, 2026.

The biographical details of Prof. Chen are as follows:

Prof. Chen, aged 66, graduated from Kaohsiung Medical College (高雄醫學院) (now Kaohsiung Medical University (高雄醫學大學)) in 1984 with a medical degree. Prof. Chen has over 38 years of clinical experience in the field of cardiology and has been recognized as a global leader in the treatment and research of cardiac arrhythmias, particularly atrial fibrillation.

Prof. Chen served as a resident physician in the Cardiology Division of Taipei Veterans General Hospital (臺北榮民總醫院) from 1986 to 1991, and subsequently as an attending physician from 1991 to 2009. He was the director of the cardiology division of Taipei Veterans General Hospital from 2009 to 2014, the director of the department of internal medicine of Taipei Veterans General Hospital from 2014 to 2017, the deputy superintendent of Taipei Veterans General Hospital from 2017 to 2021, and the superintendent of Taichung Veterans General Hospital (臺中榮民總醫院) from 2021 to 2025. Prof. Chen is currently the vice president of National Yang Ming Chiao Tung University (國立陽明交通大學) and an attending physician Taipei Veterans General Hospital (臺北榮民總醫院).

Prof. Chen has been an independent director of Kang Bio Tech Co., Ltd. (和康生物科技股份有限公司), which is listed on the Taiwan Stock Exchange with stock code: 1783, since August 2025, and an independent director of AOpen Inc. (建碁股份有限公司), which is listed on the Taiwan Stock Exchange with stock code: 3046, since May 2026.

Prof. Chen holds academic positions including professor of internal medicine at National Yang Ming Chiao Tung University (國立陽明交通大學).

Prof. Chen holds certifications as a specialist in internal medicine and cardiology in the Republic of China. Prof. Chen has also held leadership positions in professional organizations, including serving as president of the Asia Pacific Heart Rhythm Society (亞太心律醫學會), president of the Taiwan Heart Rhythm Society (台灣心律不整學術會), and president of the Asia Pacific Atrial Fibrillation Society (亞太心房顫動學術會).

Prof. Chen has received numerous honors and awards in recognition of his contributions to medicine, including the Ding Nong Award (丁農獎) from the Taiwan Society of Cardiology (中華民國心臟學會) in 1996, the Distinguished Scholar Research Award from the National Science Council (國家科學委員會傑出學者研究獎) from 2009 to 2012, the Simon Dack Award from the American College of Cardiology in 2010, the Asia Pacific Society of Cardiology Distinguished Cardiologist Award (亞太心臟協會傑出心臟病專家獎) in 2013, and the Taiwan Medical Excellence Award (台灣醫療典範獎) from the National Federation of Medical Doctors Associations (中華民國醫師公會全國聯合會) in 2022. In 2024, Prof. Chen was inducted as an academician of the Industrial Technology Research Institute (工業技術研究院) and was named an honorary international academician by the Japanese Heart Rhythm Society.

A letter of appointment has been entered into between the Company and Prof. Chen pursuant to which (i) he has been appointed for a period of three years and is subject to retirement by rotation in accordance with the Articles of Association of the Company (the “**Articles**”) or any other applicable laws from time to time whereby he shall vacate his office; (ii) Prof. Chen is entitled to receive a director’s fee in the amount of USD33,000 per annum; and (iii) the terms of services do not expressly require the Company to give more than one year’s notice period or to make payments equivalent to more than one year’s emoluments to terminate the service. The remuneration of Prof. Chen was determined with reference to the recommendation of the remuneration committee of the Company and by making reference to his role, qualification, level of experience, the prevailing market conditions, the terms of the Company’s remuneration policy and the appointment letter. In accordance with the Articles, Prof. Chen will hold office until the next general meeting of the Company after his appointment and will be eligible for re-election.

Save as disclosed above, as at the date of this announcement, Prof. Chen has confirmed that:

- (i) he has not held any other directorships in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years;
- (ii) he has not held any other positions in the Company and its subsidiaries or other major appointments and professional qualifications;
- (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company;
- (iv) he is independent as regards each of the factors referred to in Rules 3.13(1) to (8) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”);
- (v) he has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as such term is defined in the Listing Rules) of the Company;
- (vi) there are no other factors that may affect his independence at the time of his appointment;
- (vii) he does not have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong);
- (viii) there are no other matters that need to be brought to the attention of the Shareholders in connection with his appointment; and
- (ix) there is no other information that should be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board hereby further announces that:

- (a) Mr. Chen ceased to be the chairman of the remuneration committee and a member of the nomination committee of the Company with effect from August 6, 2026; and
- (b) Prof. Chen has been appointed as the chairman of the remuneration committee and a member of the nomination committee of the Company with effect from August 6, 2026.

The Board would like to extend its welcome to Prof. Chen for joining the Board.

By order of the Board
BenQ BM Holding Cayman Corp.
HSIAO Tze-Jung
Executive Director

Hong Kong, August 6, 2026

As at the date of this announcement, the Board of the Company comprise: (i) Mr. HSIAO Tze-Jung as an executive Director; (ii) Mr. CHEN Chi-Hong, Ms. HUNG Chiu-Chin and Dr. WANG Liming as non-executive Directors; and (iii) Dr. CHOW Hsing-Yi, Mr. WANG Wen-Tsung and Prof. CHEN Shi-An as independent non-executive Directors.